[Form 4] CLOROX CO /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Executive stock vesting and tax-related share withholdings: The Chief Operating Officer reported transactions on 10/03/2025 involving 15,489 shares issued upon settlement of a 2022 performance unit grant at an indicated price of $122.25 per share. The filing shows the company withheld 2,755 shares to satisfy tax obligations for restricted stock and 7,436 shares to satisfy tax obligations for performance stock units. After these transactions the reporting person beneficially owned 69,313 shares (including 739 dividend-reinvested shares).

Positive

• Vesting of 2022 performance units converted deferred pay into equity alignment (15,489 shares vested)
• Executive retains meaningful ownership after transactions (69,313 shares beneficially owned)
• Dividend reinvestment used to add 739 shares, indicating continued equity accumulation

Negative

• Large share withholdings for taxes reduced net new shares retained (2,755 restricted + 7,436 performance shares withheld)
• Net change shows disposals in the filing (total disposals recorded across withholding events)

Insights

Corporate Governance Analyst

Vesting aligns an executive with shareholder outcomes but includes significant tax withholdings.

The settlement of a 2022 performance unit grant converted deferred compensation into 15,489 shares on 10/03/2025, increasing the executive's direct holdings before withholdings. The reported price per share is $122.25, which is the transaction reporting reference.

Material dependencies include the number of remaining unvested awards and company compensation policies; monitor future Form 4s and grant disclosures over the next 12 months for additional vesting or sales activity.

Compensation & Tax Specialist

Share withholding for taxes reduced net share retention from the vesting event.

The company withheld 2,755 restricted shares and 7,436 performance shares to satisfy tax obligations, a common practice that converts part of equity compensation into tax payments. The net effect left 69,313 shares beneficially owned after the transactions, which includes 739 shares from dividend reinvestment.

Watch for future disclosures on tax-withholding methods and any subsequent open-market sales within 12 months that would further change ownership levels.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reynolds Eric H

(Last) (First) (Middle)

1221 BROADWAY

(Street)

OAKLAND CA 94612-1888

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		A(1)		15,489	A	$122.25	79,504	D
Common Stock	10/03/2025		F(2)		2,755	D	$122.25	76,749	D
Common Stock	10/03/2025		F(3)		7,436	D	$122.25	69,313(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Settlement of 2022 Performance Unit Grant, which vested 10/3/25.

2. Withholding of shares by the Company to satisfy tax obligations relating to vesting of restricted stock.

3. Withholding of shares by the Company to satisfy tax obligations relating to vesting of performance stock units.

4. Includes 739 shares acquired pursuant to a dividend reinvestment feature of the Company's Stock Incentive Plan.

	By Angela Hilt, Attorney-in-Fact for	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did the CLX reporting person make on 10/03/2025?

The reporting person had 15,489 shares issued upon settlement of a 2022 performance unit grant at $122.25; the company withheld 2,755 restricted shares and 7,436 performance shares for taxes.

How many CLX shares does the executive beneficially own after these transactions?

The executive beneficially owned 69,313 shares following the reported transactions, which includes 739 shares from dividend reinvestment.

Why were shares withheld in the CLX Form 4?

Shares were withheld by the company to satisfy tax obligations related to vesting of restricted stock (2,755 shares) and performance stock units (7,436 shares).

What was the reported price per share for the vested shares in the filing?

The filing shows a reference price of $122.25 per share for the transactions reported on 10/03/2025.

Which executive filed the Form 4 for CLX and what is their role?

The reporting person is an officer with the title EVP - Chief Operating Officer for CLOROX CO /DE/ (CLX).